Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Chief Financial Officer | April 11, 2025 | April 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kyverna Therapeutics, Inc.
Report date April 11, 2025 · Filed April 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,950 |
Reported balance
After 2025-04-11 transaction · row 1
1 source rowRow 1 · 2025-04-11 · Grant · Acquired 12,000 · Balance 55,950 F1: Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2035-04-11 | Direct | 74,000 |
Reported balance
After 2024-04-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-11 · Grant · Acquired 74,000 · Balance 74,000 F2: 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 11, 2025 Filed Apr 15, 2025 17:42 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-054344 · ownership.xml · nonDerivative · entry 1 Jones Ryan Alexander · CIK 0002007219 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,950 F1 · shares: Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 28, 2024 Filed May 29, 2024 16:33 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,146 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-065983 · ownership.xml · derivative · entry 4 Jones Ryan Alexander · CIK 0002007219 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,192 Underlying: Common Stock · 7,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. F2 · derivative.expiration_date: 25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| May 28, 2024 Filed May 29, 2024 16:33 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,870 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-065983 · ownership.xml · derivative · entry 3 Jones Ryan Alexander · CIK 0002007219 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter. F1 · derivative.expiration_date: 25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter. Read SEC document |
| May 28, 2024 Filed May 29, 2024 16:33 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionCommon Stock | 7,146 | $0.73 | $5,216.58 |
DisclosureSEC source: 0000950170-24-065983 · ownership.xml · nonDerivative · entry 2 Jones Ryan Alexander · CIK 0002007219 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: 25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| May 28, 2024 Filed May 29, 2024 16:33 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionCommon Stock | 10,870 | $0.73 | $7,935.10 |
DisclosureSEC source: 0000950170-24-065983 · ownership.xml · nonDerivative · entry 1 Jones Ryan Alexander · CIK 0002007219 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter. Read SEC document |
| April 11, 2024 Filed Apr 15, 2025 17:42 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 74,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000950170-25-054344 · ownership.xml · derivative · entry 2 Jones Ryan Alexander · CIK 0002007219 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2035-04-11 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.